Publicaciones en colaboración con investigadoras/es de Hospital Universitario de Donostia (13)

2023

  1. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

2022

  1. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  2. Local genetic variation of inflammatory bowel disease in Basque population and its effect in risk prediction

    Scientific Reports, Vol. 12, Núm. 1

  3. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  4. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

    Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641

  5. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42

2020

  1. Early microscopic findings in preclinical inflammatory bowel disease

    Digestive and Liver Disease, Vol. 52, Núm. 12, pp. 1467-1472

  2. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

2019

  1. Immunosuppression for inflammatory bowel disease does not influence Epstein–Barr viral load in the short-term

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 542-547

2018

  1. Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors

    Digestive and Liver Disease, Vol. 50, Núm. 8, pp. 812-819

  2. Characteristics and Progression of Preclinical Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1459-1466

2017

  1. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131